[Modification of the histopathologic degree of inflammation in asymptomatic prostatitis (NIH IV) by moxifloxacin].
Bschleipfer
T
T
Klinik und Poliklinik für Urologie und Kinderurologie, Justus-Liebig-Universität Giessen, Rudolf-Buchheim-Strasse 7, 35385 Giessen. th.b-@gmx.de
Wagenlehner
F M E
FM
Weidner
W
W
D000890:Anti-Infective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001372:Aza Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood; D001706:Biopsy; D004311:Double-Blind Method; D024841:Fluoroquinolones; D006801:Humans; D008297:Male; D000077266:Moxifloxacin; D011446:Prospective Studies; D011467:Prostate / Q000187:drug effects / Q000473:pathology; D017430:Prostate-Specific Antigen / Q000097:blood; D011472:Prostatitis / Q000097:blood / Q000188:drug therapy* / Q000473:pathology*; D011804:Quinolines / Q000009:adverse effects / Q000627:therapeutic use*
D000890:Anti-Infective Agents; D001372:Aza Compounds; D014408:Biomarkers, Tumor; D024841:Fluoroquinolones; D011804:Quinolines; D017430:Prostate-Specific Antigen; D000077266:Moxifloxacin